A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer
详细信息 查看全文
- 作者：Hyun Chang (1) (7) (8)
Sung Kwan Shin (2) (8)
Byoung Chul Cho (1) (8)
Chang-Geol Lee (3) (8)
Choong Bai Kim (4) (8)
Dae Joon Kim (5) (8)
Jin Gu Lee (5) (8)
Jin Hur (6) (8)
Chang Young Lee (5) (8)
Mi Kyung Bae (5) (8)
Hye Ryun Kim (1) (8)
Sang Kil Lee (2) (8)
Jun Chul Park (2) (8)
Hyuk Lee (2) (8)
Hyoung-Il Kim (4) (8)
Hyunsoo Chung (2) (8)
Jihye Cha (6) (8)
Yong Chan Lee (2) (8)
Joo-Hang Kim (1) (8) - 关键词：S ; 1 ; Cisplatin ; Esophageal cancer ; Chemoradiotherapy ; Preoperative
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：73
- 期：4
- 页码：665-671
- 全文大小：299 KB
- 参考文献：1. Tepper J, Krasna MJ, Niedzwiecki D et al (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086-092 CrossRef
2. Burmeister BH, Smithers BM, Gebski V et al (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6:659-68 CrossRef
3. Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD (2009) Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 15:4962-968 CrossRef
4. Lee SJ, Ahn BM, Kim JG et al (2009) Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci 24:120-25 CrossRef
5. Harada K, Kawaguchi S, Supriatno H, Kawashima Y, Yoshida H, Sato M (2005) S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett 226:161-68 CrossRef
6. Nakata E, Fukushima M, Takai Y et al (2006) S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. Oncol Rep 16:465-71
7. Yokota T, Onozawa Y, Boku N et al (2011) S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy. Jpn J Clin Oncol 41:1351-357 CrossRef
8. Cho SH, Shim HJ, Lee SR et al (2008) Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus 21:697-03 CrossRef
9. Bedenne L, Michel P, Bouche O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160-168 CrossRef
10. Koo DH, Park SI, Kim YH et al (2012) Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol 69:655-63 CrossRef
11. van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-084 CrossRef
12. Herskovic A, Martz K, Al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593-598 CrossRef
13. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M (1993) Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 11:1118-123
14. Donahue JM, Nichols FC, Li Z et al (2009) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 87:392-98 discussion 8- CrossRef
15. Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW (2010) Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 97:1482-496 CrossRef
16. Kim MK, Cho KJ, Park SI et al (2009) Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 75:115-21 CrossRef
17. Reynolds JV, Muldoon C, Hollywood D et al (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245:707-16 CrossRef
18. Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-56 CrossRef
19. Medical Research Council Oesophageal Cancer Working G (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727-733 CrossRef
20. Lee JL, Park SI, Kim SB et al (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15:947-54 CrossRef - 作者单位：Hyun Chang (1) (7) (8)
Sung Kwan Shin (2) (8)
Byoung Chul Cho (1) (8)
Chang-Geol Lee (3) (8)
Choong Bai Kim (4) (8)
Dae Joon Kim (5) (8)
Jin Gu Lee (5) (8)
Jin Hur (6) (8)
Chang Young Lee (5) (8)
Mi Kyung Bae (5) (8)
Hye Ryun Kim (1) (8)
Sang Kil Lee (2) (8)
Jun Chul Park (2) (8)
Hyuk Lee (2) (8)
Hyoung-Il Kim (4) (8)
Hyunsoo Chung (2) (8)
Jihye Cha (6) (8)
Yong Chan Lee (2) (8)
Joo-Hang Kim (1) (8)
1. Yonsei Cancer Center, Yonsei University Health System, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea
7. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
8. Esophageal Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea
2. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea
3. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
4. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea
5. Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea
6. Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea - ISSN：1432-0843
文摘
Purpose S-1 is a novel oral fluoropyrimidine anticancer agent designed to enhance clinical efficacy, reduce gastrointestinal toxicity, and enhance radiotherapy effectiveness. A phase II trial was conducted to evaluate the efficacy and safety of preoperative chemoradiation with S-1 and cisplatin in locoregionally advanced esophageal cancer. Methods Eligible patients had stage IIA-IVA esophageal cancer. Patients received two cycles of S-1 (days 1-4 and days 22-5) and cisplatin (days 1 and 22) with concurrent radiotherapy (50.4?Gy total; 1.8?Gy/fraction). Esophagectomy was performed between weeks 12 and 18 as determined by the specialist multidisciplinary team. Results Sixty patients were enrolled in this study between March 2008 and August 2011, and 59 were eligible. The clinical stage was ≥T3 in 28 patients (47?%) and N1 in 43 patients (72?%), with squamous cell carcinoma histology in 58 patients (97?%). Fifty-four patients (90?%) completed the planned chemoradiation. After chemoradiation, the clinical tumor response rate was 64.4?%. The primary toxicities included neutropenia (24?%) and esophagitis (8.5?%). Three treatment-related deaths were noted. Twenty-five patients (42?%) underwent esophagectomy following chemoradiation, and 15 achieved complete pathologic regression. The estimated overall survival and progression-free survival rates after 2?years were 65 and 48?%, respectively. Conclusions Concurrent chemoradiation with S-1 and cisplatin exhibited encouraging results with complete pathologic regression. The survival data were promising compared with the historical data of 5FU/cisplatin and should be confirmed in a randomized phase III trial. Toxicities were significant but clinically manageable.